Compare Direxion Daily FTSE China Bull 3x Shares (YINN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily FTSE China Bull 3x Shares vs Zimmer Biomet Holdings Inc — how do they compare? Direxion Daily FTSE China Bull 3x Shares trades at $27.22, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc pays a 1.01% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| YINN | ZBH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $56.62 | $104.26 |
52-Week Low | $21.45 | $79.58 |
Market Cap | — | $18.05B |
Enterprise Value | — | $25.11B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
YINN, the Direxion Daily FTSE China Bull 3x ETF, is trading at $28.05, down 7.49% with a bearish technical signal. The leveraged ETF faces pressure from mixed Chinese economic policies and U.S.-China trade tensions. Recent news highlights China's AI investment plans and export controls, creating volatility. Technical indicators show strong bearish momentum with moving averages signaling sell pressure.
The outlook remains cautious due to YINN's leveraged structure amplifying risks amid geopolitical uncertainty. While China's tech sector shows IPO momentum, the fund's inherent decay and China's economic stabilization efforts present both opportunity and significant risk for investors seeking Chinese equity exposure.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
